monomethyl auristatin e

Monomethyl auristatin E (MMAE) 是海兔毒素 10 的合成衍生物，是一种抗有丝分裂剂，通过阻断微管蛋白的聚合来抑制细胞分裂，并且还具有抑制抗体-药物偶联物的活性。

Monomethyl auristatin E (GMP)是 Monomethyl auristatin E 的 GMP 级别试剂。Monomethyl auristatin E 是一种海兔毒素 10 的合成衍生物，是一种抗有丝分裂剂，通过阻断微管蛋白的聚合来抑制细胞分裂，并且还具有抑制抗体-药物偶联物的活性。

Mc-MMAE (Maleimidocaproyl-monomethylauristatin E) 是保护基团 (马来酰亚氨基己酰) 与 MMAE 共轭连接得到的化合物。它是微管蛋白抑制剂，可用于偶联抗体。

MMAU （β-D-Glucuronylmonomethylauristatin E）是一种有效载荷，这种糖苷类有效载荷在未结合的游离状态下相对稳定。通过溶酶体酶的作用将其转化为去糖基化状态后，会激活负载物的细胞毒性。

D8-MMAE (D8-Monomethyl auristatin E) is an effective mitotic inhibitor and tubulin inhibitor, deuterated MMAE.

m-PEG4-Br is a cleavable ADC linker used in the synthesis of an antibody-drug conjugate (ADC) for Trastuzumab. It is positioned distally from the monomethyl auristatin E (MMAE) payload, resulting in an ADC with modified hydrophilicity, antigen binding, and in vivo characteristics.

DBCO-(PEG2-VC-PAB-MMAE)2 consists of Monomethyl auristatin E (MMAE), a toxin payload in antibody-drug conjugate [1], conjugated to the cleavable linker DBCO-(PEG2-VC-PAB)2. MMAE, a potent tubulin inhibitor, serves as the cytotoxic component in this formulation.

DBCO-(PEG)3-VC-PAB-MMAE is a chemical compound where monomethyl auristatin E (MMAE), a potent tubulin inhibitor acting as a toxin payload in antibody-drug conjugates, is conjugated to a DBCO-(PEG)3-vc-PAB linker.

Mal-Phe-C4-VC-PAB-MMAE is a chemical compound resulting from the conjugation of monomethyl auristatin E (MMAE), a potent tubulin inhibitor serving as a toxin payload in antibody-drug conjugates, with a Mal-Phe-C4-VC-PAB linker.

N3-PEG3-vc-PAB-MMAE, a drug-linker conjugate designed for Antibody-Drug Conjugates (ADC), features the integration of monomethyl auristatin E (MMAE), a tubulin inhibitor, via a 3-unit polyethylene glycol (PEG) linker. This compound demonstrates significant antitumor activity.

SC-VC-PAB-MMAE is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADCs), comprising the anti-mitotic agent monomethyl auristatin E (MMAE, a tubulin inhibitor) connected through the cleavable linker SC-VC-PAB[1].

SuO-Val-Cit-PAB-MMAE is an ADC (antibody-drug conjugate) linker comprising the anti-mitotic monomethyl auristatin E (MMAE, a tubulin inhibitor) connected through the SuO-Val-Cit-PAB peptide.

Azido-PEG4-Val-Cit-PAB-MMAE is a drug-linker conjugate for antibody-drug conjugates (ADCs), comprising the anti-mitotic agent monomethyl auristatin E (MMAE, a tubulin inhibitor), connected through the cleavable linker Azido-PEG4-Val-Cit-PAB-OH.

Disitamab vedotin (RC-48) 是一种新开发的靶向人表皮生长因子受体2（HER2） 的抗体-活性分子偶联物 (ADC) ，由 hertuzumab 偶联单甲基 auristatin E （MMAE） 通过可切割接头组成。Disitamab vedotin 在不同HER-2表达水平胃癌细胞中显示出抗肿瘤和抗增殖活性且抑制胃癌细胞中HER-2蛋白的表达。

Fmoc-MMAE, a protective group-conjugated variant of monomethyl auristatin E (MMAE), serves as a powerful inhibitor of tubulin. It finds application in the synthesis of antibody-drug conjugates (ADC).

Dov-Val-Dil-OH is a useful chemical intermediate for synthesis of auristatin-related compounds, such as Monomethyl auristatin E (MMAE), Auristatins are antimitotic agents which inhibits cell division by blocking the polymerisation of tubulin.

Zilovertamab vedotin (VLS-101) 是一种抗体-活性分子偶联物 (ADC), 主要由人源化单克隆抗体 zilovertamab 和单甲基 vedotin 组成的抗微管细胞毒素。该药物通过与肿瘤细胞表面的ROR1结合, 触发快速内化及向溶酶体的转运, 进而裂解释放单甲基 vedotin, 诱导细胞凋亡。适用于癌症的研究领域。

lifastuzumAb 是一种人源化的抗 NaPi2b 的 IgG1 类单克隆抗体，常与抗有丝分裂剂单甲基 auristatin E 偶联，通过阻断微管蛋白的聚合来抑制细胞分裂。

Polatuzumab vedotin是一种抗体药物偶联物，靶向CD79b。该化合物结合了人源化抗CD79b IgG1单克隆抗体和微管抑制剂monomethyl auristatin E (MMAE)，展现出针对大B细胞淋巴瘤（LBCL）的治疗潜力。

MC-VA-PABC-MMAE是一种ADC(Linker为peptide MC-VA-PABC)的活性分子，由Linker与高效微管蛋白抑制剂MMAE通过偶联反应形成。

Ac-Lys-Val-Cit-PABC-MMAE作为一种抗体偶联药物(ADC)的活性分子部分，由ADC连接子（肽 Ac-Lys-Val-Cit-PABC）与微管蛋白聚合抑制剂MMAE经偶联形成。

Ac-Lys-Val-Cit-PABC-MMAE (formic) 为一种抗体药物偶联物（ADC）的活性组分。该化合物是由ADC链接子（肽类Ac-Lys-Val-Cit-PABC）与微管蛋白聚合抑制剂Monomethylauristatin E (MMAE) 结合而得。

Tisotumab vedotin是一种针对组织因子（tissue factor, TF）的抗体-药物偶联物（ADC），由全人源单克隆抗体(TF-011)与Monomethyl Auristatin E (MMAE)耦合而成，具有显著抗肿瘤活性，适用于晚期或转移性实体瘤的治疗研究。

Val-Ala-PAB-MMAE 是一种用于抗体药物偶联（ADC）的缀合物，由 Val-Ala-PAB 可裂解连接子和 具有抗肿瘤作用的微管抑制剂MMAE（Monomethyl Auristatin E）组成。在细胞内被组织蛋白酶 B切割后释放 MMAE，实现靶向药物递送，减少对正常组织的毒性，提高抗癌活性。